Will Herrington

Will Herrington is Professor of Trials and Epidemiology of Kidney Disease at the Nuffield Department of Population Health, University of Oxford and a practising Honorary Consultant Nephrologist at Oxford Kidney Unit. He jointly leads the Renal Studies Group which he joined in 2010 as a Clinical Research Fellow and trained on landmark renal trials (SHARP, 3C and UKHARP3). He is Chief Investigator of the EMPA-KIDNEY and EASi-KIDNEY trials (www.easikidney.org) which use streamlined methods to test definitively effects of empagliflozin and vicadrostat on cardiovascular and renal outcomes in broad populations with chronic kidney disease. He is on a number of clinical practice guideline working groups working with KDIGO, the UKKA, the ERA and the ESC.